Dott. Luca Maurillo Curriculum Vitae

DATI PERSONALI Luogo di nascita: Roma, Italia Data di nascita: 27.01.1968 Cittadinanza: Italiana Telefono: +39-3383764591 Indirizzo lavoro: Fondazione Policlinico Tor Vergata Viale Oxford 81 – 00133 Roma, Italia Telefono: +39-06 20903228/3406 Fax: +39-06 20903246 E-mail: luca.maurillo@uniroma2.it Lingue Straniere: Inglese TITOLI DI STUDIO 1992 Laurea in Medicina e Chirurgia presso Università degli studi di

Roma "La Sapienza" con votazione 110/110 con lode discutendo la tesi: " Terapia della leucemia mieloide acuta in fase avanzata con l’associazione Mitoxantrone-Etoposide-Citosina Arabinoside a dosi intermedie (Protocollo MEC)". Relatore Prof. Sergio Amadori.

1992 Abilitazione all’esercizio della professione di Medico-Chirurgo

ed iscrizione all’albo dell’Ordine dei Medici-Chirurghi di Roma con N. 44854.

1997 Diploma di Specializzazione in Ematologia presso l’Università

degli studi di Roma "La Sapienza" con votazione 70/70 con lode, discutendo la tesi: "Aspetti sierologici delle anemie emolitiche autoimmuni". Relatore Prof. Gabriella Girelli.

2003 Dottore di ricerca in “Biotecnologie nel trapianto di midollo

osseo umano–XIV ciclo” presso l’Università degli studi di Perugia. Tesi:”Significato prognostico della malattia minima residua in pazienti affetti da leucemia acuta mieloide sottoposti a trapianto di cellule staminali”.

2011 Master in Management Sanitario applicato all’Ematologia –

anno2010-2011 presso Fondazione ISTUD

2013 Abilitazione scientifica nazionale settore concorsuale 06/D3 professore seconda fascia : abilitato

2014 Procedura comparativa per professore universitario di ruolo di

seconda fascia presso il dipartimento di biomedicina e prevenzione dell’Università degli studi di Roma “Tor vergata”: qualificato nel settore concorsuale 06/D3

ATTIVITÀ CLINICA Giugno 1990 – ottobre 1992: studente interno presso la Cattedra di Ematologia dell’Università degli Studi di Roma “La Sapienza”. Frequenta il reparto di degenza e i laboratori di citomorfologia – citochimica - diagnostica citofluorimetrica interessandosi in particolare della diagnosi delle emopatie maligne. Novembre 1992: vincitore del concorso e iscrizione alla II scuola di specializzazione in Ematologia Clinica e di Laboratorio (nuovo ordinamento) direttore Prof. S. Amadori. Durante il corso di specializzazione presso l’Istituto di Ematologia dell’Università degli Studi di Roma “La Sapienza”, ha frequentato:

• il reparto di ematologia pediatrica • il reparto di pronto soccorso e di breve osservazione ematologica • il Day Hospital ematologico • il Centro Trasfusionale Universitario ed il relativo laboratorio di

immunoematologia. Dicembre 1997 – dicembre 2001: frequenta, prima come medico volontario e successivamente come dottorando di ricerca l’ambulatorio, il Day Hospital ed il laboratorio di Citofluorimetria della UOC di Ematologia dell’Ospedale S.Eugenio – Università Tor Vergata diretta dal Prof. S. Amadori. Attività clinica: gestione clinica delle seguenti patologie: leucemia acuta mieloide, leucemia acuta linfoide, sindromi mielodisplastiche, sindromi mieloproliferative croniche, leucemia linfatica cronica Attività laboratoristica: diagnosi citofluorimetrica delle emopatie maligne (leucemie acute e croniche, sindromi mielodisplastiche, linfomi e mielomi). Attività di ricerca: valutazione citofluorimetrica della malattia minima residua nelle leucemie acute mieloidi e linfoidi caratterizzazione immunofenotipica delle cellule staminali 1 Gennaio 2002 – 31 ottobre 2009 : Dirigente Medico di I livello - UOC di Ematologia Ospedale S. Eugenio – Università Tor Vergata, Roma

Attività clinica: aiuto nel reparto di ematologia (2 anni) ambulatorio/DH (5 anni) gestione clinica delle seguenti patologie: leucemia acuta mieloide, leucemia acuta linfoide, sindromi mielodisplastiche, sindromi mieloproliferative croniche, leucemia linfatica cronica Attività laboratoristica: diagnosi citofluorimetrica delle emopatie maligne ; identificazione di marcatori e fattori prognostici nelle leucemie acute mieloidi e linfoidi, nelle sindromi mielodisplastiche e nelle

leucemie linfatiche croniche.

Attività di ricerca: monitoraggio della risposta terapeutica nelle leucemie acute mieloidi e linfoidi mediante valutazione citofluorimetrica della malattia minima residua PI o sub investigator di protocolli di ricerca clinica su: leucemia acuta mieloide, sindromi mielodisplastiche, sindromi mieloproliferative croniche Ph neg

1 Novembre 2009 – presente: Dirigente Medico di I livello - UOC di Ematologia Fondazione Policlinico Tor Vergata, Roma

Attività clinica: ambulatorio/DH (5 anni) gestione clinica delle seguenti patologie: leucemia acuta mieloide, leucemia acuta linfoide, sindromi mielodisplastiche, sindromi mieloproliferative croniche Ph neg, leucemia linfatica cronica, piastrinopenie autoimmuni Attività laboratoristica: diagnosi citofluorimetrica delle emopatie maligne; identificazione di marcatori e fattori prognostici nelle leucemie acute mieloidi e linfoidi, nelle sindromi mielodisplastiche

Attività di ricerca: monitoraggio della risposta terapeutica nelle leucemie acute mieloidi e linfoidi mediante valutazione citofluorimetrica della malattia minima residua Sub investigator di protocolli di ricerca clinica su: leucemia acuta mieloide, sindromi mielodisplastiche, sindromi mieloproliferative croniche Ph neg, leucemia linfatica cronica

ELENCO DELLE PUBBLICAZIONI h-index : 25 g-index: 52 hI, norm: 13 ARTICOLI IN RIVISTA 1. Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F,

Mariotti B, Iannella E, Maurillo L, Venditti A, Gattei V, de Fabritiis P, Cantonetti M, Amadori S (2016) Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. DRUGS TODAY (BARC) Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954.

2. Buccisano F, Piccioni AL, Nobile C, Criscuolo M, Niscola P, Tatarelli C, Fianchi L,

Villivà N, Neri B, Carmosino I, Gumenyuk S, Mancini S, Voso MT, Maurillo L, Breccia M, Zini G, Venditti A, Fenu S, Spiriti MA, Latagliata R; GROM (Gruppo Romano Mielodisplasie). (2016) Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study. ANN HEMATOL, Jun;95(7):1059-65. doi: 10.1007/s00277-016-2667-1. Epub 2016 Apr 19.

3. Del Principe MI, Sarmati L, Cefalo M, Fontana C, De Santis G, Buccisano F,Maurillo

L, De Bellis E, Postorino M, Sconocchia G, Del Poeta G, Sanguinetti M, Amadori S, Pagano L, Venditti A. (2016) A cluster of Geotrichum clavatum (Saprochaete clavata) infection in haematological patients: a first Italian report and review of literature. MYCOSES Apr 8. doi: 10.1111/myc.12508. [Epub ahead of print]

4. Arriga R, Caratelli S, Coppola A, Spagnoli GC, Venditti A, Amadori S, Lanzilli G, Lauro

D, Palomba P, Sconocchia T, Del Principe MI, Maurillo L, Buccisano F, Capuani B, Ferrone S, Sconocchia G (2016) Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage. ONCOTARGET Jan 12;7(2):2070-9. doi: 10.18632/oncotarget.6529.

5. Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Rossi FM, Zucchetto A, Rossi D,

Bomben R, Maurillo L, Cefalo M, De Santis G, Venditti A, Gaidano G, Amadori S, de Fabritiis P, Gattei V, Del Poeta G (2016) Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. HEMATOLOGICA Jan;101(1):77-85. doi: 10.3324/haematol.2015.131854.

6. Latagliata R, Montagna C, Porrini R, Di Veroli A, Leonetti SC, Niscola P, Ciccone F,

Spadea A, Breccia M, Maurillo L, Rago A, Spirito F, Cedrone M, De Muro M, Montanaro M, Andriani A, Bagnato A, Montefusco E, Alimena G (2016) Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase. EUR J HEMATOL Jun;96(6):643-9. doi: 10.1111/ejh.12674.

7. Coppola A, Arriga R, Lauro D, Del Principe MI, Buccisano F, Maurillo L, Palomba P,

Venditti A, Sconocchia G. (2015) NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma. FRONT MED (LAUSANNE) May 26;2:33. doi: 10.3389/fmed.2015.00033.

8. Andriani A, Montanaro M, Voso MT, Villivà N, Ciccone F, Andrizzi C, De Gregoris C, Di

Veroli A, Maurillo L, Alimena G, Latagliata R. (2015) Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN. LEUK RES Aug;39(8):801-4. doi: 10.1016/j.leukres.2015.03.001.

9. Voso MT, Niscola P, Piciocchi A, Fianchi L, Maurillo L, Musto P, Pagano L, Mansueto

G, Criscuolo M, Aloe-Spiriti MA, Buccisano F, Venditti A, Tendas A, Piccioni AL, Zini G, Latagliata R, Filardi N, Fragasso A, Fenu S, Breccia M; GROM (Gruppo Romano e Laziale MDS) and Basilicata MDS Registry. (2016) Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. EUR J HEMATOL, Apr;96(4):344-51. doi: 10.1111/ejh.12595.

10. Angelini DF, Ottone T, Guerrera G, Lavorgna S, Cittadini M, Buccisano F, De Bardi M,

Gargano F, Maurillo L, Divona M, Noguera NI, Consalvo MI, Borsellino G, Bernardi G, Amadori S, Venditti A, Battistini L, Lo-Coco F. (2015) A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia. CLIN CANCER RES Sep 1;21(17):3977-85. doi: 10.1158/1078-0432.CCR-14-3186.

11. Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Sarlo C, Cefalo M, Ditto C, Di

Veroli A, De Santis G, Irno Consalvo M, Fraboni D, Panetta P, Palomba P, Attrotto C, Del Poeta G, Sconocchia G, Lo-Coco F, Amadori S, Venditti A. (2015) Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. ANN HEMATOL, Aug;94(8):1319-26. doi: 10.1007/s00277-015-2364-5.

12. Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trapè G, Tatarelli C,

D'Addosio A, Latagliata R, Fenu S, Piccioni AL, Fragasso A, Aloe Spiriti MA, Refrigeri M, Criscuolo M, Musto P, Venditti A. (2015) Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata. EUR J HEMATOL, ul;95(1):52-6. doi: 10.1111/ejh.12476.

13. Breccia M, Voso MT, Aloe Spiriti MA, Fenu S, Maurillo L, Buccisano F, Tafuri A,

Alimena G. (2015) An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms. ANN HEMATOL, May;94(5):771-7. doi: 10.1007/s00277-015-2341-z.

14. Fianchi L, Pagano L, Piciocchi A, Candoni A, Gaidano G, Breccia M, Criscuolo M,

Specchia G, Maria Pogliani E, Maurillo L, Aloe-Spiriti MA, Mecucci C, Niscola P, Rossetti E, Mansueto G, Rondoni M, Fozza C, Invernizzi R, Spadea A, Fenu S, Buda G, Gobbi M, Fabiani E, Sica S, Hohaus S, Leone G, Voso MT. (2015) Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. AM J HEMATOL, May;90(5):E80-5. doi: 10.1002/ajh.23966.

15. Ramos F, Thépot S, Pleyer L, Maurillo L, Itzykson R, Bargay J, Stauder R, Venditti A,

Seegers V, Martínez-Robles V, Burgstaller S, Récher C, Debén G, Gaidano G, Gardin C, Musto P, Greil R, Sánchez-Guijo F, Fenaux P; European ALMA Investigators.

(2015) Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. LEUK RES, Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013.

16. Garza E, Fabiani E, Noguera N, Panetta P, Piredda ML, Borgia L, Maurillo L, Catalano

G, Voso MT, Lo-Coco F. (2015) Development of a high-resolution melting curve analysis screening test for SRSF2 splicing factor gene mutations in myelodysplastic syndromes. J MOL DIAGN, Jan;17(1):85-9. doi: 10.1016/j.jmoldx.2014.08.002.

17. Del Principe MI, Maurillo L, Buccisano F, Sconocchia G, Cefalo M, De Santis G, Di

Veroli A, Ditto C, Nasso D, Postorino M, Refrigeri M, Attrotto C, Del Poeta G, Lo-Coco F, Amadori S, Venditti A. (2014) Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy. MEDITERR J HEMATOL INFECT DIS, Nov 1;6(1):e2014075. doi: 10.4084/MJHID.2014.075.

18. Maurillo L, Buccisano F, Piciocchi A, Del Principe MI, Sarlo C, Di Veroli A, Panetta P,

Irno-Consalvo M, Nasso D, Ditto C, Refrigeri M, De Angelis G, Cerretti R, Arcese W, Sconocchia G, Lo-Coco F, Amadori S, Venditti A (2015). Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia. AM J HEMATOL, Feb;90(2):125-31. doi: 10.1002/ajh.23893.

19. Del Principe MI, Sconocchia G, Buccisano F, Cefalo M, Di Veroli A, De Santis G,

Nasso D, Maurillo L, Anemona L, Postorino M, Del Poeta G, Amadori S, Venditti A (2015). Extensive toxic epidermal necrolysis following brentuximab vedotin administration. ANN HEMATOL, Feb;94(2):355-6. doi: 10.1007/s00277-014-2148-3.

20. Bo MD, Del Principe MI, Pozzo F, Ragusa D, Bulian P, Rossi D, Capelli G, Rossi FM,

Niscola P, Buccisano F, Bomben R, Zucchetto A, Maurillo L, de Fabritiis P, Amadori S, Gaidano G, Gattei V, Del Poeta G (2014). NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. ANN HEMATOL, Oct;93(10):1765-74 doi: 10.1007/s00277-014-2117-x.

21. Del Principe MI, Buccisano F, Cefalo M, Maurillo L, Di Caprio L, Di Piazza F, Sarlo C,

De Angelis G, Irno Consalvo M, Fraboni D, De Santis G, Ditto C, Postorino M, Sconocchia G, Del Poeta G, Amadori S, Venditti A (2014). High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma. ANN HEMATOL, Sep;93(9):1509-13. doi: 10.1007/s00277-014-2080-6

22. Tatarelli C, Piccioni AL, Maurillo L, Naso V, Battistini R, D’Andrea M, Criscuolo M,

Nobile C, Villivà, N, Mancini S, Neri B, Breccia M, Fenu S, Buccisano F, Voso MT, Latagliata R, Aloe Spiriti MA (2014). Recombinant human erythropoietin in very elderly patients with myelodysplastic sindrome: results from a retrospective study. ANN HEMATOL, Aug;93(8):1413-20. doi: 10.1007/s00277-014-2053-9.

23. Breccia M, Voso MT, Maurillo L, Niscola P, Fianchi L, Aloe Spiriti MA, Buccisano F,

Latagliata R, Pelliccia S, Fenu S, Tendas A, Alimena G (2014). Real-life experience with azacitidine in myelodysplastic sindrome according to IPSS cytogenetic profile. AM J HEMATOL, vol 89 (5):565. doi:10.1002/ajh.23677

24. Del Principe MI, Cefalo M, Buccisano F, Anemona L, Sarlo C, Di Caprio L, De Santis G, Giacobbi E, Maurillo L, Postorino M, Del Poeta G, Amadori S, Venditti A (2014). Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia. ANN HEMATOL, Sep;93(9):1611-2. doi: 10.1007/s00277-014-2010-7

25. Isidori A, Venditti A, Maurillo L, Buccisano F, Loscocco F, Manduzio P, Sparaventi G,

Amadori S, Visani G (2013). Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. EXPERT REV HEMATOL, vol 6 (6):767-84. doi: 10.1586/17474086.2013858018

26. Del Principe MI, Buccisano F, Maurillo L, Venditti D, Cefalo M, Sarlo C, Di Caprio L, Di

Veroli A, Nasso D, Ceresoli E, Postorino M, Di Piazza F, Colandrea G, Conti F, Del Poeta G, Amadori S, Venditti A (2013).Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. THROMB RES, vol 132 (5):511-14. doi:10.1016/j.thromres.2013.08.007

27. Maurillo L, Buccisano F, Del Principe MI, Sarlo C, Di Caprio L, Ditto C, Giannotti F,

Nasso D, Ceresoli E, Postorino M, Refrigeri M, Amadori S, Venditti A (2013). Treatment of acute myeloid leukemia with 20-30% bone marrow blasts. MEDITERR J HEMATOL INFECT DIS, vol 5 (1): e2013032. doi. 10.4048/MJHID.2013.032

28. Sarlo C, Buccisano F, Maurillo L, Cefalo M, Di Caprio L, Cicconi L, Ditto C, Ottaviani

L, Di Veroli A, Del Principe MI, Grasso MA, Nasso D, De Santis G, Amadori S, Venditti A (2013). Phase II study of bortezomib as a single agent in patients with previously untreated or relapsed/refractory acute myeloid leukemia inelegible for intensive therapy. LEUK RES TREATMENT 2013:705714. doi: 10.1155/2013/705714

29. Buccisano F, Maurillo L, Neri B, Masala S, Mauriello A, Del Principe MI, Ditto C, Sarlo

C, Cefalo M, Di Caprio L, Loreni G, Cicconi L, Amadori S, Venditti A (2013). Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic sindrome. J CLIN ONCOL vol 31 (11): e189-91. doi:10.1200/JCO.2012.45.3209

30. Venditti A, Del Principe MI, Maurillo L, Buccisano F, Amadori S (2013). Minimal

residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology?. TRANSL PEDIATR Jan;2(1):43-5. doi: 10.3978/j.issn.2224-4336.2012.10.01.

31. Fianchi L, Criscuolo M, Breccia M, Maurillo L, Salvi F, Musto P, Mansueto G, Gaidano

G, Finelli C, Aloe Spiriti A, Santini V, Greco M, Hohaus S, Leone G, Voso MT (2013). High rate of remission in chronic myelomonocytic leukemia treated with 5-azacitidine: results of an Italian retrospective study. LEUK LYMPHOMA vol 54 (3): 658-61. doi:10.3109/10428194.2012.719617

32. Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E, Lunghi M, D'Arco A

M, Levis A, Pastore D, Di Renzo N, Santagostino A, Pavone V, Buccisano F, Musto P (2012). Azacitidine for the treatment of patients with acute myeloid leukemia. CANCER, vol. 118, p. 1014-1022, ISSN:0008-543X, doi: 10.1002/cncr.26354

33. Del Poeta G, Del Principe M I, Zucchetto A, Luciano F, Buccisano F, Rossi F M, Bruno A, Biagi A, Bulian P, Maurillo L, Neri B, Bomben R, Simotti C, Coletta A M, Dal Bo M, de Fabritiis P, Venditti A, Gattei V, Amadori S (2012). CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. HAEMATOLOGICA, vol. 97, p. 279-287, ISSN: 0390-6078, doi: 10.3324/haematol.2011.052829

34. Buccisano F, Maurillo L, Del Principe M I, Del Poeta G, Sconocchia G, Lo-Coco F,

Arcese W, Amadori S, Venditti A (2012). Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. BLOOD, vol. 119, p. 332-341, ISSN: 0006-4971, doi: 10.1182/blood-2011-08-363291

35. Buccisano F, Maurillo L, Spagnoli A, Del Principe M I, Fraboni D, Panetta P, Ottone T,

Consalvo M I, Lavorgna S, Bulian P, Ammatuna E, Angelini D F, Diamantini A, Campagna S, Ottaviani L, Sarlo C, Gattei V, Del Poeta G, Arcese W, Amadori S, Lo Coco F, Venditti A (2010). Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. BLOOD, vol. 116, p. 2295-2303, ISSN: 0006-4971, doi: 10.1182/blood-2009-12-258178

36. Del Poeta G, Ammatuna E, Lavorgna S, Capelli G, Zaza S, Luciano F, Ottone T, Del

Principe M I, Buccisano F, Maurillo L, Panetta P, de Fabritiis P, Stasi R, Venditti A, Amadori S, Lo Coco F, RI Capelli G F-6329-2011 (2010). The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, vol. 149, p. 383-387, ISSN: 0007-1048, doi: 10.1111/j.1365-2141.2010.08098.x

37. Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Lunghi M, Villani O, Aloe-Spiriti

M A, Venditti A, Santini V (2010). Azacitidine for the Treatment of Lower Risk Myelodysplastic Syndromes. CANCER, vol. 116, p. 1485-1494, ISSN: 0008-543X, doi: 10.1002/cncr.24894

38. Del Poeta G, Del Principe M I, Maurillo L, Rossi F M, Buccisano F, Ammatuna E,

Simotti C, Zucchetto A, Catalano G, Bulian P, Bruno A, Venditti A, De Fabritiis P, Gattei V, Amadori S (2010). Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA, vol. 51, p. 95-106, ISSN: 1042-8194, doi: 10.3109/10428190903350421

39. Buccisano F, Maurillo L, Spagnoli A, Del Principe M I, Ceresoli E, Lo Coco F, Arcese

W, Amadori S, Venditti A (2009). Monitoring of minimal residual disease in acute myeloid leukemia. CURRENT OPINION IN ONCOLOGY, vol. 21, p. 582-588, ISSN: 1040-8746, doi:10.1097/CCO.0b013e3283311856

40. Voso M T, Santini V, Finelli C, Musto P, Pogliani E, Angelucci E, Fioritoni G, Alimena G, Maurillo L, Cortelezzi A, Buccisano F, Gobbi M, Borin L, Di Tucci A, Zini G, Petti M C, Martinelli G, Fabiani E, Fazi P, Vignetti M, Piciocchi A, Liso V, Amadori S, Leone G (2009). Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. CLINICAL CANCER RESEARCH, vol. 15, p. 5002-5007, ISSN: 1078-0432, doi: 10.1158/1078-0432.CCR-09-0494

41. Maurillo L, Buccisano F, Del Principe M I, Del Poeta G, Spagnoli A, Panetta P, Ammatuna E, Neri B, Ottaviani L, Sarlo C, Venditti D, Quaresima M, Cerretti R, Rizzo M, de Fabritiis P, Lo Coco F, Arcese W, Amadori S, Venditti A (2008). Toward Optimization of Postremission Therapy for Residual Disease-Positive Patients With Acute Myeloid Leukemia. JOURNAL OF CLINICAL ONCOLOGY, vol. 26, p. 4944-4951, ISSN: 0732 183X, doi: 10.1200/JCO.2007.15.9814

42. Pulsoni A, Lacobelli S, Bernardi M, Borgia M, Camera A, Cantore N, Di Raimondo F,

Fazi P, Ferrara F, Leoni F, Liso V, Mancini M, Marmont F, Matturro A, Maurillo L, Melillo L, Meloni G, Mirto S, Specchia G, Valentini C G, Venditti A, Leone G, Foa R, Mandelli F, Pagano L (2008). M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. HAEMATOLOGICA, vol. 93, p. 1025-1032, ISSN: 0390-6078, doi: 10.3324/haematol.11889

43. Del Poeta G, Bruno A, Del Principe M I, Venditti A, Maurillo L, Buccisano F, Stasi R,

Neri B, Luciano F, Siniscalchi A, de Fabritiis P, Amadori S (2008). Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. CURRENT CANCER DRUG TARGETS, vol. 8, p. 207-222, ISSN: 1568 0096

44. Buccisano F, Maurillo L, Tamburini A, Del Poeta G, Del Principe M I, Ammatuna E,

Consalvo M I, Campagna S, Ottaviani L, Sarlo C, Renzi D, Faccia S, Fraboni D, Lo Coco F, Amadori S, Venditti A (2008). Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes. EUROPEAN JOURNAL OF HAEMATOLOGY, vol. 80, p. 107-114, ISSN: 0902-4441, doi: 10.1111/j.1600-0609.2007.00986.x

45. Niscola P, Del Principe M I, Palombi M, Fratoni S, Piccioni D, Maurillo L, de Fabritiis

P, Amadori S, Del Poeta G (2008). Hodgkin lymphoma in a mutated ZAP-70 negative B-cell chronic lymphocytic leukemia patient. LEUKEMIA RESEARCH, vol. 32, p. 363-365, ISSN: 0145-2126, doi: 10.1016/j.leukres.2007.03.014

46. Gattei V, Bulian P, Del Principe M I, Zucchetto A, Maurillo L, Buccisano F, Bomben R,

Dal-Bo M, Luciano F, Rossi F M, Degan M, Amadori S, Del Poeta G (2008). Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. BLOOD, vol. 111, p. 865-873, ISSN: 0006-4971, doi: 10.1182/blood-2007-05-092486

47. Del Poeta G, Del Principe M I, Buccisano F, Maurillo L, Capelli G, Luciano F, Perrotti

A P, Degan M, Venditti A, de Fabritiis P, Gattei V, Amadori S (2008). Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. CANCER, vol. 112, p. 119-128, ISSN: 0008-543X, doi: 10.1002/cncr.23144

48. Niscola P, Perrotti A P, del Poeta G, Romani C, Palombi M, Piccioni D, Scaramucci L,

Tolu B, Tendas A, Cupelli L, Abruzzese E, D'Elia G M, Brunetti G A, Maurillo L, Giovannini M, Cartoni C, de Fabritiis P (2007). Case reports: zoster pain in haematological malignancies: effective pain relief with oxycodone in patients unresponsive to other analgesic measures. HERPES, vol. 14, p. 45-47, ISSN: 0969-7667

49. Maurillo L, Buccisano F, Spagnoli A, Del Poeta G, Panetta P, Neri B, Del Principe M I,

Mazzone C, Consalvo M I, Tamburini A, Ottaviani L, Fraboni D, Sarlo C, De Fabritiis P, Amadori S, Venditti A (2007). Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. HAEMATOLOGICA, vol. 92, p. 605-611, ISSN: 0390-6078, doi: 10.3324/haematol.10432

50. Niscola P, Maurillo L, Palombi M, Fratoni S, Perrotti A P, Piccioni D, Panetta P,

Scaramucci L, Del Poeta G, De Fabritiis P (2007). Gelatinous degeneration of the bone marrow: Two case reports showing different hematological features and clinical outcomes. ACTA HAEMATOLOGICA, vol. 118, p. 165-166, ISSN: 0001-5792, doi: 10.1159/000108766

51. Del Poeta G, Del Principe M I, Buccisano F, Maurillo L, Niscola P, Venditti A, Amadori

S (2006). Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia. EXPERT REVIEW OF ANTICANCER THERAPY, vol. 6, p. 1787-1800, ISSN: 1473-7140, doi: 10.1586/14737140.6.12.1787

52. Buccisano F, Maurillo L, Del Poeta G, Gattei V, Amadori S, Venditti A (2006). Optimal

post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia.. HAEMATOLOGICA, vol. 91, p. ELT15-ELT14; author reply ELT15, ISSN: 1592-8721

53. Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe M I, Cox M C, Panetta P,

Consalvo M I, Mazzone C, Neri B, Ottaviani L, Fraboni D, Tamburini A, Lo-Coco F, Amadori S, Venditti A (2006). The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. LEUKEMIA, vol. 20, p. 1783-1789, ISSN: 0887-6924, doi: 10.1038/sj.leu.2404313

54. Niscola P, Scaramucci L, Romani C, Giovannini M, Maurillo L, Del Poeta G, Cartoni

C, Arcuri E, Amadori S, De Fabritiis P (2006). Opioids in pain management of blood-related malignancies. ANNALS OF HEMATOLOGY, vol. 85, p. 489-501, ISSN: 0939-5555, doi: 10.1007/s00277-005-0062-4

55. Del Principe M I, Del Poeta G, Buccisano F, Maurillo L, Venditti A, Zucchetto A,

Marini R, Niscola P, Consalvo M A Irno, Mazzone C, Ottaviani L, Panetta P, Bruno A, Bomben R, Suppo G, Degan M, Gattei V, de Fabritiis P, Cantonetti M, Lo Coco F, Del Principe D, Amadori S (2006). Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. BLOOD, vol. 108, p. 853-861, ISSN: 0006-4971, doi: 10.1182/blood-2005-12-4986

56. Del Poeta G, Del Principe MI, Consalvo MAI, Maurillo L, Buccisano F, Venditti A, Mazzone C, Bruno A, Gianni L, Capelli G, Lo Coco F, Cantonetti M, Gattei V, Amadori S, RI Capelli Giovanni/F-6329-2011 (2005). The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. CANCER, vol. 104, p. 2743-2752, ISSN: 0008-543X, doi: 10.1002/cncr.21535

57. Niscola P, Del Principe MI, Maurillo L, Venditti A, Buccisano F, Piccioni D, Amadori S,

Del Poeta G (2005). Fulminant B hepatitis in a surface antigen-negative patient with B-

cell chronic lymphocytic leukaemia after rituximab therapy. LEUKEMIA, vol. 19, p. 1840-1841, ISSN: 0887-6924, doi:10.1038/sj.leu.2403914

58. Del Principe MI, Del Poeta G, Venditti A, Buccisano F, Maurillo L, Mazzone C, Bruno A, Neri B, Consalvo MI, Lo Coco F, Amadori S (2005). Apoptosis and immaturity in acute myeloid leukemia. HEMATOLOGY, vol. 10, p. 25-34, ISSN: 1024-5332, doi: 10.1080/10245330400020454

59. Del Principe MI, Del Poeta G, Venditti A, Buccisano F, Maurillo L, Marini R, Cox MC,

Panetta P, Suppo G, Degan M, Bruno A, Gattei V, Amadori S (2004). Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. HAEMATOLOGICA, vol. 89, p. 1468-1475, ISSN: 0390-6078

60. Cox MC, Panetta P, Lo-Coco F, Del Poeta G, Venditti A, Maurillo L, Del Principe MI,

Mauriello A, Anemona L, Bruno A, Mazzone C, Palombo P, Amadori S (2004). Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation - results in 378 adult patients. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, vol. 122, p. 298-306, ISSN: 0002-9173, doi:10.1309/RX27R8GJQM330C22

61. Venditti A, Del Poeta G, Maurillo L, Buccisano F, Del Principe MI, Mazzone C,

Tamburini A, Cox C, Panetta P, Neri B, Ottaviani L, Amadori S (2004). Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. HAEMATOLOGICA, vol. 89, p. 934-939, ISSN: 0390-6078

62. Buccisano F, Rossi FM, Venditti A, Del Poeta G, Cox MC, Abbruzzese E, Rupolo M,

Berretta M, Degan M, Russo S, Tamburini A, Maurillo L, Del Principe MI, Postorino M, Amadori S, Gattei V (2004). CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. BRITISH JOURNAL OF HAEMATOLOGY, vol. 125, p. 203-212, ISSN: 0007-1048, doi:10.1111/j.1365-2141.2004.04883.x

63. Venditti A, Maurillo L, Buccisano F, Del Poeta G, Mazzone C, Tamburini A, Del

Principe MI, Consalvo MI, De Fabritiis P, Cudillo L, Picardi A, Franchi A, Coco FL, Amadori S (2003). Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. LEUKEMIA, vol. 17, p. 2178-2182, ISSN: 0887-6924, doi: 10.1038/sj.leu.2403138

64. Del Principe MI, Del Poeta G, Maurillo L, Buccisano F, Venditti A, Tamburini A, Bruno

A, Cox MC, Suppo G, Tendas A, Gianni L, Postorino M, Masi M, Del Principe D, Amadori S (2003). P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, vol. 121, p. 730-738, ISSN: 0007-1048, doi: 10.1046/j.1365-2141.2003.04343.x

65. Cox MC, Panetta P, Venditti A, Del Poeta G, Maurillo L, Tamburini A, Del Principe MI,

Amadori S (2003). Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23(+)/MLL+ translocation in leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, vol. 121, p. 953-955, ISSN: 0007-1048, doi: 10.1046/j.1365-2141.2003.04382.x

66. Cox MC, Panetta P, Venditti A, Del Poeta G, Franchi A, Buccisano F, Tamburini A, Maurillo L, Amadori S (2003). Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patients. HEMATOL J vol.4 (4):263-270

67. Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, Cox

MC, Franchi A, Bruno A, Mazzone C, Panetta P, Suppo G, Masi M, Amadori S (2003). Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). BLOOD, vol. 101, p. 2125-2131, ISSN: 0006-4971, doi: 10.1182/blood-2002-06-1714

68. Venditti A, Maurillo L, Buccisano F, Tamburini A, Del Poeta G, Del Principe MI,

Panetta P, Consalvo MI, Mazzone C, Tendas A, Trawinska M, Forte V, Amadori S (2003). Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia. LEUKEMIA & LYMPHOMA, vol. 44, p.445-450, ISSN: 1042-8194, doi: 10.1080/1042819021000037976

69. Venditti A, Tamburini A, Buccisano F, Del Poeta G, Maurillo L, Panetta P,

Scornajenghi KA, Cox C, Amadori S (2002). Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia. JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, vol. 11, p. 349-357, ISSN:1525-8165, doi: 10.1089/152581602753658538

70. Bruno A, Caravita T, Adorno G, Del Poeta G, Venditti A, Stasi R, Ballatore G, Del

Proposto G, Lanti A, Zinno F, Cudillo L, Dentamaro T, Buccisano F, Tamburini A, Santinelli S, Maurillo L, Cantonetti M, Cox MC, Masi M, Catalano G, Isacchi G, Amadori S (2002). Positive selection of CD34+cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors. TRANSFUSION AND APHERESIS SCIENCE, vol. 26, p. 103-110, ISSN:1473-0502, doi: 10.1016/S1473-0502(01)00157-4

71. Del Poeta G, Maurillo L, Venditti A, Buccisano F, Epiceno AM, Capelli G, Tamburini

A, Suppo G, Battaglia A, Del Principe MI, Del Moro B, Masi M, Amadori S, RI Capelli Giovanni/F-6329-2011 (2001).Clinical significance of CD38 expression in chronic lymphocytic leukemia. BLOOD, vol. 98, p. 2633-2639, ISSN: 0006-4971, doi: 10.1182/blood.V98.9.2633

72. Maurillo L, Del Poeta G, Venditti A, Buccisano F, Battaglia A, Santinelli S, Caravita T,

Epiceno AM, Del Moro B, Tamburini A, Picardi A, Suppo G, Catalano G, Bruno A, Amadori S (2001). Quantitative analysis of Fas and bcl-2 expression in hematopoietic precursors. HAEMATOLOGICA, vol. 86, p.237-243, ISSN: 0390-6078

73. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, Battaglia A,

Catalano G, Del Moro B, Cudillo L, Postorino M, Masi M, Amadori S (2000). Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. BLOOD, vol. 96, p. 3948-3952, ISSN: 0006-4971

74. Venditti A, Tamburini A, Buccisano F, Scimo MT, Del Poeta G, Maurillo L, Cox MC,

Abruzzese E, Tribalto M, Masi M, Amadori S (2000). A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic

syndromes. ANNALS OF HEMATOLOGY, vol. 79, p. 138-142, ISSN: 0939-5555, doi: 10.1007/s002770050569

75. Venditti A, Battaglia A, Del Poeta G, Buccisano F, Maurillo L, Tamburini A, Del Moro

B, Epiceno AM, Martiradonna M, Caravita T, Santinelli S, Adorno G, Picardi A, Zinno F, Lanti A, Bruno A, Suppo G, Franchi A, Franconi G, Amadori S (1999). Enumeration of CD34(+) hematopoietic progenitor cells for clinical transplantation: comparison of three different methods. BONE MARROW TRANSPLANTATION, vol. 24, p. 1019-1027, ISSN: 0268-3369, doi: 10.1038/sj.bmt.1702013

76. Del Poeta G, Venditti A, Stasi R, Aronica G, Cox MC, Buccisano F, Tamburini A,

Bruno A, Maurillo L, Battaglia A, Suppo G, Epiceno AM, Del Moro B, Masi M, Amadori S, Papa G (1999). P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. LEUKEMIA RESEARCH, vol. 23, p. 451-465, ISSN: 0145-2126, doi: 10.1016/S0145-2126(98)00191-X

77. Tosti S, Caruso R, D’Adamo F, Picardi A, Ege MA, Girelli G, Mauro FR, Maurillo L,

Amadori S (1992). Severe autoimmune hemolytic-anemia in a patient with chronic lymphocytic leukemia responsive to fludarabine-based treatment. ANNALS OF HEMATOLOGY, vol. 65, p. 238-239, ISSN: 0939-5555, doi: 10.1007/BF01703953

78. Pulsoni A, Ferrazza G, Malagnino F, Maurillo L, Pescarmona E, Picardi A, Rendina

EA, Amadori S (1992). Mediastinal extramedullary hematopoiesis as 1st manifestation of hereditary spherocytosis. ANNALS OF HEMATOLOGY, vol. 65, p. 196-198, ISSN: 0939-5555, doi: 10.1007/BF01703115

ABSTRACT IN RIVISTA

1. Buccisano F, Maurillo L, Del Principe M I, Cerretti R, Sarlo C, Picardi A, Cefalo M, Ottaviani L, De Angelis G, Ditto C, Di Veroli A, Consalvo M Irno, Fraboni D, Panetta P, Del Poeta G, Lo Coco F, Amadori S, Arcese W, Venditti A (2012). Risk-adapted transplant selection improves outcome of adult patients with high-risk AML. BONE MARROW TRANSPLANTATION, vol. 47, p. S262, ISSN: 0268-3369

2. Del Poeta G, Del Principe M I, Buccisano F, Biagi A, Bulian P, Luciano F, Zucchetto A, Maurillo L, Niscola P, Perrotti A P, Venditti A, Gattei V, de Fabritiis P, Amadori S (2011). Clinical Monoclonal B Cell Lymphocytosis Is a Strong Favorable Prognosticator Independent From Biological and Clinical Parameters. BLOOD, vol. 118, p. 1661, ISSN: 0006-4971

3. Del Poeta G, Del Principe M I, Bulian P, Buccisano F, Biagi A, Neri B, Perrotti A P, Zucchetto A, Maurillo L, Niscola P, Venditti A, de Fabritiis P, Gattei V, Amadori S (2011). Immunotherapeutic Maintenance Strategy Prolongs Response Duration and Overall Survival Preventing Relapse in Chronic Lymphocytic Leukemia (CLL). BLOOD, vol. 118, p. 1670, ISSN: 0006-4971

4. Del Poeta G, Del Principe M I, Rossi F M, Coletta A, Buccisano F, Simotti C, Cox M C, Luciano F, Zucchetto A, Maurillo L, Biagi A, Niscola P, Consalvo M A Irno,

Perrotti A P, Venditti A, de Fabritiis P, Gattei V, Amadori S (2010). Normal Fish Cytogenetics and 13q Deletions Unveil Marked Biological and Clinical Heterogeneity In Chronic Lymphocytic Leukemia.. BLOOD, vol. 116, p. 1109, ISSN:0006-4971

5. Buccisano F, Maurillo L, Del Principe M I, Cerretti R, Consalvo M A Irno, Fraboni D, Panetta P, Campagna S, Ottaviani L, Sarlo C, De Angelis G, Ditto C, Di Caprio L, Cefalo M G, Ammatuna E, Duranti F, Lo Coco F, Arcese W, Amadori S, Venditti A (2010). MRD-Directed Post-Remissional Therapy Dramatically Improves Outcome of Adult Patients with High Risk AML by Implementing Allogeneic Transplant Option. BLOOD, vol. 116, p. 1114, ISSN: 0006-4971

6. Del Poeta G, Del Principe M I, Bulian P, Simotti C, Buccisano F, Luciano F, Zucchetto A, Ottaviani L, Maurillo L, Sarlo C, Biagi A, Gianni L, Perrotti A P, Venditti A, de Fabritiis P, Gattei V, Amadori S (2010). Clinical Significance of CD69 Expression In Chronic Lymphocytic Leukemia. BLOOD, vol. 116,p. 1471-1472, ISSN: 0006-4971

7. Maurillo L, Buccisano F, Spagnoli A, Del Principe M I, Neri B, Cefalo M G, De Angelis G, Picardi A, Ditto C, Ammatuna E, Del Poeta G, Arcese W, Lo Coco F, Amadori S, Venditti A (2010). IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE CYTARABINE IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN CONTAINING HIGH DOSE CYTARABINE. HAEMATOLOGICA, vol. 95 MA 0063, p. 25-26, ISSN: 0390-6078

8. Del Poeta G, Del Principe M I, Zucchetto A, Buccisano F, Bomben R, Luciano F, Dal Bo M, Maurillo L, Rossi F, Ottaviani L, De Fabritiis P, Venditti A, Gaidano G, Gattei V, Amadori S (2010). CD69 AND CD79B OVEREXPRESSION IDENTIFY POOR RISK CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA, vol. 95 MA 0762, p. 317-318, ISSN: 0390-6078

9. Del Poeta G, Del Principe M I, Bulian P, Ragusa D, Rossi D, Perrotti A, Zucchetto A, Buccisano F, Degan M, Maurillo L, Gianni L, Ottaviani L, Luciano F, Venditti A, De Fabritiis P, Gattei V, Gaidano G, Amadori S (2010). PERSISTENT PHENOTYPIC COMPLETE REMISSION OR MAINTENANCE TREATMENT PREDICT FOR LONG-LASTING RESPONSE DURATION AND LONGER OVERALL SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA, vol. 95 MA 0773, p. 322, ISSN: 0390-6078

10. Del Poeta G, Del Principe M I, Buccisano F, Piccioni D, Maurillo L, Sarlo C, Consalvo M Irno, Bulian P, Zucchetto A, Gianni L, Simotti C, de Fabritiis P, Venditti A, Gattei V, Amadori S (2009). The Amount of Spontaneous Apoptosis Is An Independent Strong Disease Progression Indicator in B-Cell Chronic Lymphocytic Leukemia (B-CLL). BLOOD, vol. 114, p. 515, ISSN: 0006-4971

11. Maurillo L, Buccisano F, Spagnoli A, Del Principe M I, Neri B, Sarlo C, Del Poeta G, Lo Coco F, Amadori S, Venditti A (2009). In Acute Myeloid Leukemia, the Use in Induction of Standard Dose Arac Is Associated with a Better Quality of Response as Compared to An Induction Regimen Containing High Dose. BLOOD, vol. 114, p. 634, ISSN: 0006-4971

12. Del Poeta G, Del Principe M I, Simotti C, Buccisano F, Maurillo L, Zucchetto A, Ottaviani L, Bulian P, Sarlo C, Consalvo M Irno, Venditti A, de Fabritiis P, Gattei V, Amadori S (2009). The Earliest Activation Marker CD69 Is An Independent and Strong Progression Indicator in B-Cell Chronic Lymphocytic Leukemia. BLOOD, vol. 114, p. 931-932, ISSN: 0006-4971

13. Del Poeta G, Del Principe M I, Ragusa D, Maurillo L, Buccisano F, Ottaviani L, Gianni L, Luciano F, Bulian P, Rossi F M, Venditti A, de Fabritiis P, Gattei V,

Amadori S (2009). Rituximab Maintenance Following Chemoimmunotherapy Improves Outcome in B-Cell Chronic Lymphocytic Leukemia. BLOOD, vol. 114, p. 933-934, ISSN: 0006-4971

14. Buccisano F, Maurillo L, Del Principe M I, Del Poeta G, Consalvo M A Irno, Fraboni D, Lavorgna S, Ottone T, Campagna S, Ammatuna E, Rizzo M, Gianni L, Postorino M, Arcese W, Lo Coco F, Amadori S, Venditti A (2009). THE COMBINATION OF FLOW-CYTOMETRY MINIMAL RESIDUAL DISEASE ASSESSMENT AND CYTOGENETIC/GENETIC PARAMETERS ALLOWS A PROPER RISK STRATIFICATION OF ADULT AML PATIENTS: IMPLICATION FOR TRANSPLANT CHOICE AND POST CONSOLIDATION THERAPY. HAEMATOLOGICA, vol. 94 MA 0838, p. 338, ISSN: 0390-6078

15. Musto P, Maurillo L, Spagnoli A, D'Arco A, Pollio B, Candoni A, Spiriti A Aloe, Lunghi M, Fili C, Orciuolo E, Venditti A, Morabito F, Mazza P, Pastore D, Santini V (2009). Azacitidine for the treatment of lower risk myelodysplastic syndromes: final results from an Italian named patient program. LEUKEMIA RESEARCH, vol. 33, p. S127, ISSN: 0145-2126

16. Del Poeta G, Del Principe M I, Zucchetto A, Buccisano F, Simotti C, Maurillo L, Gianni L, Bulian P, Venditti A, Coletta A, Niscola P, de Fabritiis P, Gattei V, Amadori S (2008). High CD79b Expression Predicts a Poor Outcome in B-Cell Chronic Lymphocytic Leukemia (B-CLL).. BLOOD, vol. 112, p. 386, ISSN: 0006-4971

17. Buccisano F, Maurillo L, Del Principe M I, Del Poeta G, Panetta P, Ammatuna E, Ottaviani L, Sarlo C, Quaresima M, De Angelis G, Rizzo M, Campagna S, Lo Coco F, Arcese W, Amadori S, Venditti A (2008). Decisional Algorithm to Incorporate Hematopoietic Stem Cell Transplantation in the Management of Adult Patients with Acute Myeloid Leukaemia.. BLOOD, vol. 112, p. 540-541, ISSN:0006-4971

18. Del Poeta G, Del Principe M I, Buccisano F, Maurillo L, Neri B, Ottaviani L, Luciano F, Piccioni D, Consalvo M Irno, Ammatuna E, Bruno A, de Fabritiis P, Gattei V, Venditti A, Lo Coco F, Amadori S (2008). The Amount of Mitochondrial Apoptosis Exerts Prognostic Impact on Normal Karyotype Acute Myeloid Leukemia. BLOOD, vol. 112, p. 526-527, ISSN: 0006-4971

19. Maurillo L, Spagnoli A, Genuardi M, Lunghi M, Di Renzo N, D'Arco A M, Mele G, Levis A, Gozzini A, Petrini M, Mianulli M, Sanpaolo G, Santagostino A, Pietrantuono G, D'Auria F, Ferrero D, Gaidano G, Ferrara F, Venditti A, Leone G, Santini V, Musto P (2008). 5-Azacytidine for the Treatment of Acute Myeloid Leukemia: A Retrospective, Multicenter Study of 55 Patients.. BLOOD, vol. 112, p. 679-680, ISSN: 0006-4971

20. Buccisano F, Maurillo L, Ammatuna E, Del Poeta G, Del Principe M I, Fraboni D, Consalvo M I, Divona M, Lavorgna S, Ottone T, Panetta P, Amadori S, Lo-Coco F, Venditti A (2008). THE COMBINED ANALYSIS OF FLOW-CYTOMETRIC MINIMAL RESIDUAL DISEASE DETERMINATION AND MUTATIONAL STATUS OF FLT3 AND NPM IMPROVES THE PROGNOSTIC STRATIFICATION OF ADULT AML PATIENTS WITH NORMAL KARYOTYPE. HAEMATOLOGICA, vol. 93, p. S23-S24, ISSN: 0390-6078

21. Del Poeta G, Del Principe M I, Bulian P, Maurillo L, Buccisano F, Gianni L, Luciano F, Zucchetto A, Degan M, Dal-Bo M, Siniscalchi A, Venditti A, De Fabritiis P, Gattei V, Amadori S (2008). CD49D PROTEIN EXPRESSION REFINES THE PROGNOSTIC IMPACT OF THE TUMOR LOAD MARKERS IN CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA, vol. 93, p. S98, ISSN: 0390-6078

22. Del Principe M I, Del Poeta G, Buccisano F, Maurillo L, Neri B, Siniscalchi A, Ottaviani L, Ammatuna E, Luciano F, Irno Consalvo M, Bruno A, Venditti A, Lo Coco F, Gattei V, de Fabritiis P, Amadori S (2008).MITOCHONDRIAL APOPTOSIS

PROTEINS LEVEL PREDICT OUTCOME IN ACUTE MYELOID LEUKEMIA. HAEMATOLOGICA, vol. 93, p. S79-S80, ISSN: 0390-6078

23. Del Principe M I, Bulian P, Maurillo L, Buccisano F, Gianni L, Siniscalchi A, Luciano F, Zucchetto A, Degan M, Venditti A, de Fabritiis F, Gattei V, Amadori S, Del Poeta G (2008). HIGH CD54 ADHESION MOLECULE EXPRESSION PREDICTS A SHORT PROGRESSION FREE SURVIVAL IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA, vol. 93, p. S95, ISSN: 0390-6078

24. Del Poeta G, Del Principe M I, Maurillo L, Siniscalchi A, Buccisano F, Coletta A, Bulian P, Venditti A, Niscola P, Gattei V, Simotti C, Perrotti A P, De Fabritiis P, Amadori S (2008). ORAL FLUDARABINE PLUS RITUXIMAB RESULT IN HIGH COMPLETE REMISSION RATE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA, vol. 93 MA 0094, p. 37, ISSN: 0390-6078

25. Musto P, Maurillo L, Spagnoli A, Genuardi M, Lunghi M, Di Renzo N, Mele G, Levis A, D'Arco A, Gozzini A, Petrini M, Mianulli M, Sanpaolo G, Santagostino A, Pietrantuono G, D'Auria E, Ferrero D, Gaidano G, Ferrara E, Santini V, Leone G, Bosi A, Venditti A (2008). 5-AZACYTIDINE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA: RESULTS IN 45 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM. HAEMATOLOGICA, vol. 93 MA 0231, p. 93, ISSN: 0390-6078

26. Buccisano F, Maurillo L, Del Poeta G, Del Principe M I, Fraboni D, Panetta P, Consalvo M Irno, Rizzo M, Gianni L, Campagna S, Faccia S, Renzi D, Postorino M, Cantonetti M, Lo Coco F, Amadori S, Venditti A (2008). FLOW-CYTOMETRIC MINIMAL RESIDUAL DISEASE DETERMINATION IS A SURROGATE PROGNOSTICATOR IN ADULT AML PATIENTS WITH NORMAL KARYOTYPE. HAEMATOLOGICA, vol. 93 MA 0041, p. 15-16, ISSN: 0390-6078

27. Del Poeta G, Del Principe M I, Siniscalchi A, Maurillo L, Buccisano F, Venditti A, Luciano F, Niscola P, Zucchetto A, Gattei V, Perrotti A P, De Fabritiis P, Amadori S (2008). RITUXIMAB CONSOLIDATION AND MAINTENANCE THERAPY PROLONG RESPONSE DURATION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA. HAEMATOLOGICA, vol. 93 MA 0085, p. 34, ISSN: 0390-6078

28. Maurillo L, Spagnoli A, Gozzini A, Cecconi N, D'Argenio M, Lunghi M, Rocco S, Palumbo G, Rivellini E, Genuardi M, Sibilla S, Ferrara F, Mele G, Filardi N, Sanpaolo G, Specchia G, Tonso A, Santagostino A, Voso M T, Balleari E, Cassibba V, Della Cioppa P, Mazzone C, Oliva E, Ciuffreda L, Russo D, Galimberti, S, Villani O, D'Auria F, Di Renzo N, D'Arco A M (2008). 5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM. HAEMATOLOGICA, vol. 93 MA 0238, p. 96, ISSN:0390-6078

29. Bulian P, Del Principe M I, Zucchetto A, Maurillo L, Bomben R, Buccisano F, Dal Bo M, Luciano F, Rossi F M, Venditti A, Degan M, Amadori S, Gattei V, Del Poeta G (2008). HIGH CD54 CELL SURFACE EXPRESSION ON B CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA IS AN INDEPENDENT PREDICTOR OF POOR OUTCOME. HAEMATOLOGICA, vol. 93 MA 0527, p. 213, ISSN: 0390-6078

30. Cedrone M, Chierichini A, Borza P Anticoli, Fenu S, Bongarzoni V, Anaclerico B, Ronci B, Venditti A, Venditti D, Maurillo L, De Fabriitis P, Annino L (2008). LOW-MOLECULAR-WEIGHT HEPARIN (LMWH) TREATMENT IN ACUTE LEUKAEMIA (AL) PATIENTS WITH SEVERE THROMBOCYTOPENIA AND CONCOMITANT VENOUS OR ARTERIAL THROMBOSIS. HAEMATOLOGICA, vol. 93 MA 0865, p. 343, ISSN: 0390-6078

31. Musto P, Maurillo L, Spagnoli A, Gozzini A, Rivellini F, Tatarelli C, Lunghi M, Fili C, Orciuolo E, Ciuffreda L, Vigna E, Della Cioppa P, Ferrero D, Palmieri S, Palumbo G, Di Renzo N, Oliva E, Sanpaolo G, Pastore D, Tonso A, Santagostino A, Villani O,

D'Auria F, D'Arco A, Gaidano G, Galimberti S, Russo D, Venditti A, Aloe-Spiriti M A, Leone G, Santini V (2008). 5-AZACYTIDINE FOR THE TREATMENT OF LOW/INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 63 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM. HAEMATOLOGICA, vol. 93 MA 0925, p. 368, ISSN:0390-6078

32. Del Poeta G, Del Principe M I, Maurillo L, Buccisano F, Catalano G, Venditti A, Zucchetto A, Perrotti AP, Gattei V, de Fabritiis P, Amadori S (2007). Rituximab consolidation and maintenance immunotherapy improve outcome in B-cell chronic lymphocytic leukemia. BLOOD, vol. 110, p. 606A,ISSN: 0006-4971

33. Buccisano F, Maurillo L, Del Poeta G, Del Principe M I, Panetta P, Fraboni D, Consalvo M Irno, Renzi D, Campagna S, Sarlo C, Franceschini L, Gianni L, Ammatuna E, Lo Coco F, Amadori S, Venditti A (2007). Detection of minimal residual disease by flow-cytometry otimizes risk stratification when combined with cytogenetics in AML. BLOOD, vol. 110, p. 128B, ISSN: 0006-4971

34. Del Poeta G, Del Principe M I, Luciano F, Maurillo L, Buccisano F, Catalano G, Gianni L, Coletta A, Zucchetto A, Niscola P, Venditti A, de Fabritiis P, Gattei V, Amadori S (2007). High CD69 protein expression predicts a poor prognosis in B-cell chronic lymphocytic leukemia (B-CLL). BLOOD, vol. 110, p. 231A, ISSN: 0006-4971

35. Gattei V, Bulian P, Del-Principe M I, Zucchetto A, Maurillo L, Buccisano F, Bomben R, Dal-Bo M, Luciano F, Rossi FM, Degan M, Amadori S, Del-Poeta G (2007). High CD49d protein expression predicts short overall survival and early progression in chronic lymphocytic leukemia patients.BLOOD, vol. 110, p. 911A, ISSN: 0006-4971

36. Del Poeta G, Ammatuna E, Zaza S, Buccisano F, Ottone T, Del Principe M I, Lavorgna S, Catalano G, Maurillo L, Luciano F, de Fabritiis P, Venditti A, Amadori S, Lo Coco F (2007). Nucleophosmin gene mutations exhibit high spontaneous apoptosis and favorable prognosis in acute myeloid leukemia. BLOOD, vol. 110, p. 1019A, ISSN: 0006-4971

37. Buccisano F, Maurillo L, Del Poeta G, Del Principe M I, Fraboni D, Ammatuna E, Consalvo M Irno, Panetta P, Ottaviani L, Faccia S, Rizzo M, Postorino M, Cantonetti M, Lo Coco F, Amadori S, Venditti A (2007). Flow-cytometric minimal residual disease determination is a surrogate prognosticator in adult AML patients lacking specific molecular signatures. BLOOD, vol. 110, p. 1024A-1025A, ISSN:0006-4971

38. Buccisano F, Maurillo L, Gattei V, Del Poeta G, Fraboni D, Del Principe M I, Panetta P, Irno Consalvo M, Ottaviani L, Campagna S, Ammatuna E, Franceschini L, Cantonetti M, Lo-Coco F, Amadori S, Venditti A (2007). Flow-cytometric assessment of minimal residual disease allows a risk stratification among intermediate risk karyotype AML patients. HAEMATOLOGICA, vol. 92, p. 5, ISSN: 0390-6078

39. Del Poeta G, Arnmatuna E, Zaza S, Del Principe M I, Buccisano F, Ottone T, Lavorgna S, Catalano G, Maurillo L, Bruno A, Luciano F, Ottaviani L, Sarlo C, De Fabriths P, Venditti A, Amadori S, Lo Coco F (2007). Nucleophosmin mutated blasts express high levels of spontaneous apoptosis in acute myeloid leukemia (AML). HAEMATOLOGICA, vol. 92, p. 11, ISSN: 0390-6078

40. Del Poeta G, Del Principe M I, Maurillo L, Buccisano F, Niscola F, Catalano G, Venditti A, Gattei V, Perrotti A P, de Fabritiis F, Amadori S (2007). Consolidation with rituximab improves outcome in high risk B-cell chronic lymphocytic leukemia (B-CLL). HAEMATOLOGICA, vol. 92, p. 23, ISSN: 0390-6078

41. Maurillo L, Buccisano F, Del Poeta G, Spagnoli A, Neri B, Del Principe M I, Ammatuna E, Tendas A, Luciano F, De Fabritiis P, Amadori S, Vendetti A (2007). Minimal residual disease is detectable in peripheral blood of patients with acute

myeloid leukemia and provides prognostic information. HAEMATOLOGICA, vol. 92, p. 65-66, ISSN: 0390-6078

42. Gianni L, Buccisano F, Maurillo L, Del Poeta G, Del Principe I, Ottaviani I, Sarlo C, Ammatuna E, Campagna S, Imo Consalvo M, Amadori S, Venditti A (2007). Allogeneic stem cell transplantation is the optimal post-remission therapy in minimal residual disease positive patients with acute myeloid leukemia. HAEMATOLOGICA, vol. 92, p. 69, ISSN: 0390-6078

43. Niscola P, Maurillo L, Palombi M, Fratoni S, Del Poeta G, Piccioni D, Scaramucci L, Panetta P, Perrotti A P, De Fabritiis P (2007). Gelatinous degeneration of bone marrow: Report of two cases with different haematological features and clinical outcome. HAEMATOLOGICA, vol. 92, p. 93, ISSN: 0390-6078

44. Niscola P, Del Principe M I., Palombi M, Fratoni S, Piccioni D, Maurillo L, de Fabritiis P, Amadori S, Del Poeta G (2007). ZAP-70 negative B-cell chronic lymphocytic leukemia transformed to Hodgkin lymphoma: A case report. HAEMATOLOGICA, vol. 92, p. 106-107, ISSN: 0390-6078

45. Del Poeta G, Del Principe M I, Luciano F, Maurillo L, Buccisano F, Gattei V, Niscola P, Venditti A, Imo Consalvo M, Catalano G, de Fabritiis P, Amadori S (2007). Clinical significance of CD69 expression in B-cell Chronic Lymphocytic Leukemia (B-CLL). HAEMATOLOGICA, vol. 92, p. 108, ISSN: 0390-6078

46. Niscola F, Cartoni C, Piccioni D, Del Poeta G, Scaramucci L, Romani C, Maurillo L, Palombi M, Brunetti G A, D'Elia G M, Giovannini M, Perrotti A P, de Fabritiis P (2007). Zoster-related pain in haematological malignancies: Prompt and stable relief of refractory pain syndromes by oxycodone. HAEMATOLOGICA, vol. 92, p. 196-197, ISSN: 0390-6078

47. Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe M I, Panetta P, Fraboni D, Consalvo M Imo, Campagna S, Franceschini L, Ottaviani L, Sarlo C, Ammatuna E, Lo Coco F, Amadori S, Venditti A (2007).Flow-cytometric assessment of minimal residual disease discriminates categories of risk among adult aml patients with intermediate karyotype. HAEMATOLOGICA, vol. 92 MA 0058, p. 21-22, ISSN: 0390-6078

48. Del Poeta G, Del Principe M I, Maurillo L, Buccisano F, Niscola P, Ammatuna E, Gattei V, Venditti A, De Fabritiis P, Lo-Coco E, Amadori S (2007). Maintenance immunotherapy with low-dose rituximab improves outcome in 'high risk' chronic lymphocytic leukemia. HAEMATOLOGICA, vol. 92 MA 0361, p. 129-130, ISSN: 0390-6078

49. Venditti A, Buccisano F, Maurillo L, Del Principe M I, Del Poeta G, Ottaviani L, Sarlo C, Ammatuna E, Fraboni D., Imo-Consalvo M, Amadori S (2007). Optimal post-remission therapy for flow-cytometry residual disease positive patients with acute myeloid leukemia. HAEMATOLOGICA, vol. 92 MA 0486, p. 180, ISSN: 0390-6078

50. Maurillo L, Buccisano F, Del Poeta G, Spagnoli A, Neri B, Del Principe M I, Cupelli L, Luciano F, De Fabritiis P, Amadori S, Venditti A (2007). Monitoring of minimal residual disease in acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. HAEMATOLOGICA, vol. 92 MA 0494, p. 183-184, ISSN: 0390-6078

51. Niscola P, Del Principe M I, Palombi M, Fratoni S, Piccioni D, Maurillo L, De Fabritiis P, Amadori S, Del Poeta G (2007). Hodgkin lymphoma in mutated ZAP-70 negative B-CELL chronic lymphocytic leukemia: A case report. HAEMATOLOGICA, vol. 92 MA 1227, p. 447-448, ISSN: 0390-6078

52. Niscola P, Cartoni C, Del Poeta G, Piccioni D, Palombi M, Scaramucci L, Cupelli L, Tendas A, Romani C, Brunetti G A, DElia G M, Maurillo L, Giovanni M, Perrotti A P, De Fabritiis P (2007). Zoster-related pain in haematological malignancies: Durable

pain relief by oxycodone. HAEMATOLOGICA, vol. 92 MA 1345, p. 484, ISSN: 0390-6078

53. Cedrone M, Chierichini A, Borza P Anticoti, Fenu S, Bongarzoni V, Anacterico B, Bartotini M, Ronci B, Venditti A, Venditti D, Quaresima M, Maurillo L, De Fabritiis P, Annino L (2007). Low-molecular-weight heparin (LMWH) in acute leukaemia (AL) patients with severe thrombocytopenia and concomitant venous or arterial thrombosis. THROMBOSIS RESEARCH, vol. 120, p. S158, ISSN: 0049-3848, doi:10.1016/S0049-3848(07)70195-0

54. Niscola P, Cupelli L, Romani C, Cartoni C, Piccioni D, Dentamaro T, Neri B, Tendas A, Giovannini M, Maurillo L, Amadori S, De Fabritiis P (2006). Epidemiology and characteristics of pain in blood-related disorders: A longitudinal study on Italian adult hospitalized patients.. BLOOD, vol. 108, p. 472B,ISSN: 0006-4971

55. Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe M I, Panetta P, Fraboni D, Consalvo M Irno, Ottaviani L, Renzi D, Faccia S, Sarlo C, Lo Coco F, Amadori S, Venditti A (2006). Statistical validation of a threshold to discriminate flow-cytometry minimal residual disease (MRD) levels with prognostic significance in acute myeloid leukemia (AML).. BLOOD, vol. 108, p. 651A-652A, ISSN: 0006-4971

56. Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe M I, Fraboni D, Panetta P, Consalvo M Irno, Campagna S, Gianni L, Ottaviani L, Postorino M, De Fabritiis P, Arcese W, Lo Coco F, Amadori S,Venditti A (2006). Optimal post-remission therapy for flow-cytometry minimal residual disease positive patients with acute myeloid leukemia.. BLOOD, vol. 108, p. 184A, ISSN: 0006-4971

57. Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe M I, Fraboni D, Panetta P, Consalvo M Irno, Campagna S, Gianni L, Ottaviani L, Postorino M, De Fabritiis P, Arcese W, Lo Coco F, Amadori S,Venditti A (2006). Optimal post-remission therapy for flow-cytometry minimal residual disease positive patients with acute myeloid leukemia.. BLOOD, vol. 108, p. 184A, ISSN: 0006-4971

58. Del Poeta G, Del Principe MI, Buccisano F, Venditti A, Maurillo L, Ammatuna E, Bruno A, Neri B, Sarlo C, Lo Coco F, De Fabritiis P, Amadori S (2006). Multidrug resistance proteins overexpression worsen the favorable clinical impact of an elevated spontaneous apoptosis in acute myeloid leukemia (AML). BLOOD, vol. 108, p. 656A, ISSN: 0006-4971

59. Del Poeta G, Del Principe M I, Maurillo L, Buccisano F, Venditti A, Marini R, Suppo G, Zucchetto A, Luciano F, Cantonetti M, Gattei Valter, de Fabritiis P, Amadori S (2006). Consolidation and maintenance immunotherapy with rituximab improve progression free survival within ZAP-70 positive chronic lymphocytic leukemia (CLL). BLOOD, vol. 108, p. 799A, ISSN: 0006-4971

60. Buccisano F, Maurillo L, Del Poeta G, Del Principe M, Mazzone C, Fraboni D, Panetta P, Gattei V, Lo Coco F, Amadori S, Venditti A (2006). The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.. JOURNAL OF CLINICAL ONCOLOGY, vol. 24, p. 345S, ISSN: 0732-183X

61. Del Poeta G, Del Principe MI, Venditti A, Buccisano F, Maurillo L, Mazzone C, Neri B, Consalvo MI, Bruno A, Lo Coco F, Gattei V, Amadori S (2005). Clinical relevance of spontaneous apoptosis is independent from multidrug resistance in acute myeloid leukemia (AML).. BLOOD, vol. 106, p. 101A, ISSN: 0006-4971

62. Buccisano F, Maurillo L, Giovanni DP, Ilaria DPM, Christina CM, Paola P, Anna T, Maria IC, Carla M, Benedetta N, Licia O, Daniela F, Francesco LC, Sergio A, Adriano V (2005). Prognostic determinants in adult AML patients with intermediate risk karyotype.. BLOOD, vol. 106, p. 161A, ISSN: 0006-4971

63. Niscola P, Del Giudice MI, Maurillo L, Solmone M, Capobianchi MR, Carletti F, Piccioni D, Venditti A, Amadori S, Del Poeta G (2005). Fulminant B hepatitis in a hepatitis B surface antigen-negative patient after rituximab therapy for B-CLL.. BLOOD, vol. 106, p. 338B, ISSN: 0006-4971

64. Del Poeta G, Del Principe MI, Niscola P, Maurillo L, Venditti A, Buccisano F, Consalvo MI, Mazzone C, Panetta P, Degan M, Pasqua I, Bruno A, Gattei V, Lo Coco F, Amadori S (2005). Spontaneous apoptosis and proliferation predict disease progression within ZAP-70 negative B-cell chronic lymphocytic leukemia (B-CLL). BLOOD, vol. 106, p. 349A, ISSN: 0006-4971

65. Venditti A, Maurillo L, Buccisano F, Del Poeta G, Mazzone C, Neri B, Lo Coco F, Amadori S (2005). The kinetics of reduction of minimal residual disease impacts on duration of survival and response of adult patients with acute myeloid leukemia. BLOOD, vol. 106, p. 663A-664A, ISSN: 0006-4971

66. Maurillo L, Buccisano F, Neri B, Mazzone C, Del Poeta G, Ottaviani L, Niscola P, Del Principe I, Tamburini A, Consalvo MI, Lo Coco F, Amadori S, Venditti A (2005). Monitoring of minimal residual disease (MRD) in acute myeloid leukemia using peripheral blood (PB) as an alternative source to bone marrow (BM). BLOOD, vol. 106, p. 664A, ISSN: 0006-4971

67. Del Poeta G, Del Principe MI, Venditti A, Maurillo L, Buccisano F, Consalvo MI, Mazzone C, Cox MC, Bruno A, Lo Coco F, Amadori S (2004). Clinical significance of apoptosis is independent from proliferation in acute myeloid leukemia (AML). BLOOD, vol. 104, p. 61A, ISSN: 0006-4971

68. Buccisano F, Maurillo L, Del Poeta G, Tamburini A, Cox MC, Del Principe MI, Consalvo MI, Mazzone C, Neri B, Ottaviani L, Lo Coco F, Amadori S, Venditti A (2004). The kinetic of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. BLOOD, vol. 104, p. 117A, ISSN: 0006-4971

69. Del Principe MI, Del Poeta G, Maurillo L, Venditti A, Buccisano F, Abruzzese E, Consalvo MI, Piccioni D, Gattei V, Lo Coco F, Amadori S (2004). Addition of rituximab to fludarabine improves progression free survival in untreated ZAP-70 negative chronic lymphocytic leukemia (CLL). BLOOD, vol. 104, p. 139A,ISSN: 0006-4971

70. Martinelli G, Cilloni D, Ottaviani E, Malagola M, Messa F, Rondoni M, Bosi C, Gottardi E, Rosti G, Ricci P, Gaitani S, Pane F, Testoni N, Mecucci C, Soverini S, Piccaluga PP, Amabile M, Tiribelli M, Zaccaria A,Grafone T, De Vivo A, Pileri S, Fattori P, Bocchia M, Serra A, Maurillo L, Fanin R, Cross NCP, Merante S, Cazzola M, Alimena G, Frassoni F, Galieni P, Russo D, Gobbi M, Gugliotta L, Lauria F, Mazza P, Ferrara F, Gherlinzoni F, Leoni P, Musto P, Baccarani M, Saglio G (2004). Idiopathic hypereosinophilic syndrome (HES) with FIP1L1-PDGFRA rearrangement can be effectively treated with Imatinib. BLOOD, vol. 104, p. 421A, ISSN: 0006-4971

71. Del Principe MI, Del Poeta G, Cox MC, Panetta P, Maurillo L, Venditti A, Consalvo MI, Gattei V, Lo Coco F, Amadori S (2004). ZAP-70 protein retains its prognostic significance within interphase cytogenetic groups in B-cell chronic lymphocytic leukemia (B-CLL).. BLOOD, vol. 104, p. 768A, ISSN: 0006-4971

72. Del Poeta G, Del Principe ML, Buccisano F, Venditti A, Maurillo L, Tamburini A, Cox MC, Suppo G, Marini R, Bruno A, Tendas A, Masi M, Amadori S (2003). Clinical significance of spontaneous apoptosis is independent from immaturity in acute myeloid leukemia (AML). BLOOD, vol. 102, p. 100A-101A, ISSN: 0006-4971

73. Martinelli G, Cilloni D, Ottaviani E, Malagola M, Cross N, Rosti G, Gaitani S, Pane F, Giannini B, Testoni N, Mecucci C, Soverini S, Piccaluga P, Rondoni M, Amabile

M, Tirabelli M, Bosi C, Poerio A, Zuffa E, Zaccaria A, Grafone T, De Vivo A, Ascani S, Pileri S, Visani G, Fattori P, Bocchia M, Serra A, Gottardi E, Maurillo L, Merante S, Cazzola M, Fanin R, Saglio G, Bertieri R, Baccarani M (2003). Italian cooperative study on idiopathic hypereosinophilic syndrome (HES): FIP1-L1/PDGFRA rearrangement can be effectively treated with imatinib. BLOOD, vol. 102, p. 386A, ISSN: 0006-4971

74. Del Poeta G, Gattei V, Del Principe MI, Degan M, Maurillo L, Bomben R, Venditti A, Buccisano F, Consalvo MI, Dal Bo M, Marini R, Cox MC, Meoni G, Stefanon A, Piccioni D, Suppo G, Zucchetto A, Amadori S (2003). Zap-70 protein tyrosine kinase is a powerful prognostic indicator in B-cell chronic lymphocytic leukemia (B-CLL). BLOOD, vol. 102, p. 666A, ISSN: 0006-4971

75. Maurillo L, Tamburini A, Buccisano F, Del Principe MI, Venditti A, Del Poeta G, De Fabritiis P, Amadori S (2003). Monitoring of minimal residual disease after autologous stem cell transplantation in adult AML patients. BONE MARROW TRANSPLANTATION, vol. 31, p. S122-S123, ISSN: 0268-3369

76. Buccisano F, Rossi FM, Venditti A, Del Poeta G, Rupolo M, Berretta M, Cox MC, Abbruzzese E, Tamburini A, Maurillo L, Amadori S, Gattei V (2002). High frequency of CD90/Thy-1 expression on blast cells of myelodysplastic syndromes and high risk acute myeloid leukemias. BLOOD, vol. 100, p.195A, ISSN: 0006-4971

77. Tamburini A, Venditti A, Buccisano F, Maurillo L, Del Poeta G, Del Principe MI, Franchi A, Amadori S (2002). Expression of adhesion molecules in acute myeloid leukemia (AML). BLOOD, vol. 100, p. 335A, ISSN: 0006-4971

78. Del Principe MI, Del Poeta G, Maurillo L, Venditti A, Buccisano F, Tamburini A, Cox MC, Suppo G, Consalvo MI, Marini R (2002). CD38 antigen expression, and soluble p53 levels predict outcome in B-chronic lymphocytic leukemia.. BLOOD, vol. 100, p. 590A-591A, ISSN: 0006-4971

79. Del Poeta G, Del Principe MI, Venditti A, Maurillo L, Tamburini A, Buccisano F, Cox MC, Mazzone C, Marini R, Bruno A, Suppo G, Amadori S (2002). C-kit receptor tyrosine kinase and mitochondrial apoptotic proteins predict outcome in acute myeloid leukemia (AML).. BLOOD, vol. 100, p. 747A, ISSN: 0006-4971

80. Picardi A, Dentamaro T, Cudillo L, Postorino M, Ballatore G, Cupelli L, Maurillo L, Del Principe D, Abruzzese E, Panetta P, de Fabritiis P, Amadori S (2002). A single center experience of unrelated umbilical cord blood transplant (Cbt) in childhood myelodisplastic syndromes (Mds). BONE MARROW TRANSPLANTATION, vol. 29 MA P811, p. S229, ISSN: 0268-3369

81. Del Poeta G, Maurillo L, Venditti A, Suppo G, Buccisano F, Tamburini A, Del Principe MI, Scornajenghi KA, Piccioni D, Bruno A, Masi M, Amadori S (2001). Clinical significance of soluble p53 in B-chronic lymphocytic leukemia. BLOOD, vol. 98, p. 356A, ISSN: 0006-4971

82. Maurillo L, Del Poeta G, Venditti A, Giovanna S, Buccisano F, Del Principe MI, Tamburini A, Scornajenghi A, Epiceno AM, Piccioni D, Amadori S (2001). Plasma levels of vascular endothelial growth factor (VEGF) are predictive of disease-progression in B-cell chronic lymphocytic leukemia (B-CLL). BLOOD, vol. 98, p. 360A, ISSN: 0006-4971

83. Bruno A, Del Poeta G, Maurillo L, Ragusa D, Venditti A, Marini R, Scornajenghi A, Buccisano F, Tamburini A, Adorno G, Ballatore G, Del Proposto G, Masi M, Amadori S (2001). Detection of apoptosis level in B-cell chronic lymphocytic leukemia by automated hematology analyzer. BLOOD, vol. 98, p. 363A, ISSN: 0006-4971

84. Venditti A, Tamburini A, Buccisano F, Del Poeta G, Maurillo L, Scornajenghi KA, Panetta P (2001). Clinical relevance of minimal residual disease monitoring in adult patients with acute myeloid leukemia. BLOOD, vol. 98, p. 580A, ISSN: 0006-4971

85. Buccisano F, Venditti A, Tamburini A, Del Poeta G, Maurillo L, Abruzzese E, Scornajenghi KA, Amadori S (2001). An altered Lecam1/ICAM1 ratio on CD34+cells predicts leukemic progression in MDS patients.. BLOOD, vol. 98, p. 620A, ISSN: 0006-4971

86. Del Poeta G, Venditti A, Maurillo L, Buccisano F, Abruzzese E, Tamburini A, Suppo G, Del Principe MI, Scornajenghi KA, Bruno A, Cox MC, Masi M, Amadori S (2001). The amount of c-kit receptor tyrosine: Kinase predicts outcome in acute myeloid leukemia (AML).. BLOOD, vol. 98, p. 716A, ISSN:0006-4971

87. Adorno G, Lamanda M, Del Proposto G, Ballatore G, Bruno A, Del Poeta G, Postorino M, Del Principe MI, Maurillo L, Masi M, Isacchi G, Amadori S (2001). Peripheral blood progenitor cell collection using the new AMICUS separator. TRANSFUSION, vol. 41, p. 45S, ISSN: 0041-1132

88. Dentamaro T, Rainaldi A, Cudillo L, Picardi A, Postorino M, De Laurenzi F, Masi M, Buccisano F, Maurillo L, Cupelli L, Adorno G, Amadori S (2001). T-cell-depleted Hematopoietic Stem Cell Transplantation (HSCT) from one haplotype mismatched family donors in patients with high-risk hematologic malignancies. BONE MARROW TRANSPLANTATION, vol. 27, p. S106-S107, ISSN:0268-3369

89. Forte L, Caravita T, Santinelli S, Siniscalchi A, Di Cesare S, Maurillo L, Adorno G, Ballatore G, Bruno A, Rossi P, Amadori S (2001). Functional characterization of AC133+peripheral blood stem cells. BONE MARROW TRANSPLANTATION, vol. 27, p. S71-S72, ISSN: 0268-3369

90. Maurillo L, De Poeta G, Caravita T, Venditti A, Santinelli S, Picardi A, Buccisano F, Dentamaro T, Ballatore G, Postorino M, Tamburini A, Del Moro B, Suppo G, Epiceno AM, Amadori S (2001). CD34+/AC133+and CD34+/HLA-DR+ subpopulations identify early clonogenic progenitors in umbilical cord blood. BONE MARROW TRANSPLANTATION, vol. 27, p. S103-S104, ISSN: 0268-3369

91. Cox MC, Panetta P, Florio S, Del Poeta G, Venditti A, Buccisano F, Maurillo L, Tamburini A, Del Principe MI, Trawinska M, Postorino M, D'Itri M, Masi M, Amadori S (2001). Incidence of cryptic genetic aberrations in de novo acute leukaemias detected with FISH screening of chromosomal abnormalities. BLOOD, vol. 98, p. 580A-581A, ISSN: 0006-4971

92. Venditti A, Buccisano F, Del Poeta G, Tamburini A, Maurillo L, Postorino M, Picardi A, Riccitelli A, Amadori S (2000). Minimal residual disease (MRD) monitoring after autologous stem cell transplantation (auSCT) in acute myeloid leukemia (AML). BLOOD, vol. 96, p. 311A, ISSN:0006-4971

93. Dentamaro T, Cudillo L, Rainaldi A, Picardi A, Postorino M, De Laurenzi F, Maurillo L, Buccisano F, Adorno G, Ballatore G, Mariani M, Sconocchia G, Amadori S (2000). Full-haplotype mismatched hematopoietic stem cell transplantation in patients with high risk hematological malignancies.BLOOD, vol. 96, p. 360B, ISSN: 0006-4971

94. Del Poeta G, Maurillo L, Venditti A, Buccisano F, Del Moro B, Suppo G, Epiceno AM, Del Principe MI, Masi M, Amadori S (2000). CD38 expression identifies two distinct prognostic subsets in B-chronic lymphocytic leukemia (B-CLL). BLOOD, vol. 96, p. 366A-367A, ISSN: 0006-4971

95. Del Poeta G, Venditti A, Maurillo L, Buccisano F, Del Moro B, Suppo G, Epiceno AM, Cox MC, Masi M, Amadori S (2000). The amount of spontaneous apoptosis predicts outcome in acute myeloid leukemia (AML). BLOOD, vol. 96, p. 543A, ISSN: 0006-4971

96. Buccisano F, Venditti A, Del Poeta G, Maurillo L, Abruzzese E, Tamburini A, Del Principe MI, Amadori S (2000). Lecam1/ICAM ratio identifies a distinct pattern on normal and myelodysplastic sindrome (MDS) bone marrow CD34+cells.. BLOOD, vol. 96, p. 833A, ISSN: 0006-4971

97. Adorno G, Ballatore G, Del Proposto G, Bruno A, Del Poeta G, Maurillo L, Cudillo L, Dentamaro T, Postorino A, Rainaldi A, Isacchi G, Amadori S (2000). Selection of allogeneic peripheral CD34+cells using the clinimacs device. TRANSFUSION, vol. 40, p. 102S, ISSN: 0041-1132

98. Del Poeta G, Venditti A, Maurillo L, Buccisano F, Tamburini A, Cox MC, Bruno A, Epiceno AM, Del Moro B, Battaglia A, Suppo G, Del Principe MI, Martiradonna M, Amadori S (1999). Clinical significance of multidrug resistance protein (MRP) and lung resistance protein (LRP) in acute myeloid leukemia (AML). BLOOD, vol. 94, p. 74A-75A, ISSN: 0006-4971

99. Maurillo L, Del Poeta G, Venditti A, Buccisano F, Epiceno AM, Del Principe MI, Tamburini A, Bruno A, Caravita T, Santinelli S, Suppo G, Del Moro B, Martiradonna M, Masi M, Amadori S (1999). Fas and Bcl-2 expression is directly correlated to the degree of maturity of early hematopoietic stem cells. BLOOD, vol. 94, p. 130B, ISSN: 0006-4971

100. Buccisano F, Venditti A, Del Poeta G, Tamburini A, Maurillo L, Caravita T, Santinelli S, Dentamaro T, Postorino M, Amadori S (1999). The role of CD34+/L-selectin plus hematopoietic stem cells in engraftment after autologous and allogeneic transplantation. BLOOD, vol. 94, p. 132A, ISSN: 0006-4971

101. Del Poeta G, Venditti A, Maurillo L, Buccisano F, Tamburini A, Bruno A, Cox MC, Battaalia A, Epiceno AM, Del Moro B, Suppo G, Del Principe MI, Amadori S (1999). Bax/Bcl-2 and P-glycoprotein modulate the prognostic impact of cytogenetics in acute myeloid leukemia (AML).. BLOOD, vol. 94, p. 294A, ISSN: 0006-4971

102. Simone MD, Maurillo L, Triaca V, De Santis S, Postorino M, Cudillo L, Amadori S, Aloe L (1999). Autologous stem cell transplantation in patients with myeloproliferative diseases results in altered nerve growth factor levels. BLOOD, vol. 94, p. 359B, ISSN: 0006-4971

103. Venditti A, Buccisano F, Tamburini A, Del Poeta G, Maurillo L, Del Moro B, Epiceno AM, Amadori S (1999). The amount of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.. BLOOD, vol. 94, p. 695A, ISSN: 0006-4971

104. Bruno A, Adorno G, Del Poeta G, Venditti A, Ballatore G, Lanti A, Zinno F, Buccisano F, Maurillo L,Picardi A, Isacchi G, Amadori S (1999). Comparison between three single platform assays for the absolute CD34+cell count in umbilical cord blood. TRANSFUSION, vol. 39, p. 52S, ISSN: 0041-1132

105. Del Poeta G, Venditti A, Maurillo L, Buccisano F, Tamburini A, Cox MC, Epiceno AM, Del Moro B, Battaglia A, Del Principe MID, Bruno A, Masi M, Amadori S (1999). Clinical relevance of bcl-2 expression in de novo acute myeloid leukemia (AML). EXPERIMENTAL HEMATOLOGY, vol. 27, p. 72,ISSN: 0301-472X

106. Del Poeta G, Venditti A, Maurillo L, Buccisano F, Tamburini A, Cox MC, Epiceno AM, Del Moro B, Battaglia A, Del Principe MI, Bruno A, Masi M, Amadori S (1999). P-glycoprotein (PGP) and CD71 overexpression combined with low bcl-2 identify patients at worse prognosis in acute lymphoid leukemia (ALL). EXPERIMENTAL HEMATOLOGY, vol. 27, p. 73, ISSN: 0301-472X

107. Maurillo L, Del Poeta G, Venditti A, Buccisano F, Bruno A, Epiceno AM, Caravita T, Santinelli S, Tamburini A, Del Principe MJ, Battaglia A, Del Moro B, Amadori S (1999). FAS expression correlates with the degree of immaturity of early

hematopoietic stem cells. EXPERIMENTAL HEMATOLOGY, vol. 27, p. 108, ISSN: 0301-472X

108. Bruno A, Ragusa D, Adorno G, Del Poeta G, Venditti A, Ballatore G, Caravita T, Zinno F, Lanti A, Santinelli S, Buccisano F, Tamburini A, Maurillo L, Picardi A, Isacchi G, Amadori S (1999). Umbilical cord blood banking: Variability in leukocyte count and differential by two automated hematology analysers. EXPERIMENTAL HEMATOLOGY, vol. 27, p. 119, ISSN: 0301-472X

109. Buccisano F, Del Poeta G, Venditti A, Tamburini A, Maurillo L, Cudillo L, Postorino M, Masi M, Amadori S (1999). Hematopoietic stem cell transplantation following high-dose Arac and mitoxantrone induction/consolidation for the treatment of adult acute lymphoblastic leukemia.. BONE MARROW TRANSPLANTATION, vol. 23 MA 6, p. S2, ISSN: 0268-3369

110. Venditti A, Buccisano F, Tamburini A, Del Poeta G, Maurillo L, Battaglia A, Del Moro B, Epiceno AM, Aronica G, Amadori S (1998). Clinical implications of immunological detection of minimal residual disease in acute myeloid leukemia. BLOOD, vol. 92, p. 79A, ISSN: 0006-4971

111. Buccisano F, Del Poeta G, Venditti A, Tamburini A, Maurillo L, Cudillo L, Morino L, Postorino M, Masi M, Amadori S (1998). Dose-intensive, Ara-C/mitoxantrone-based chemotherapy followed by hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia. BLOOD, vol. 92, p. 84A, ISSN: 0006-4971

112. Buccisano F, Venditti A, Del Poeta G, Tamburini A, Maurillo L, Del Moro B, Epiceno AM, Dentamaro T, Picardi A, Cudillo L, Santinelli S, Caravita T, Masi M, Amadori S (1998). Expression of adhesion molecules by CD34(+) hematopoietic stem cells: A possible role in allogeneic myeloid engraftment. BLOOD, vol. 92, p. 115A, ISSN: 0006-4971

113. Maurillo L, Del Poeta G, Venditti A, Epiceno AM, Aronica G, Buccisano F, Tamburini A, Bruno A, Caravita T, Battaglia A, Del Moro B, Suppo G, Rizzuti V, Amadori S (1998). Bcl-2, P-glycoprotein (PgP) and Fas expression in normal CD34+ progenitors.. BLOOD, vol. 92, p. 288B, ISSN: 0006-4971

114. Bruno A, Adorno G, Del Poeta G, Venditti A, Ballatore G, Zinno F, Lanti A, Buccisano F, Tamburini A, Caravita T, Santinelli S, Maurillo L, Aronica G, Masi M, Isacchi G, Amadori S (1998). Analysis of parameters influencing the positive selection of peripheral blood progenitor cells in patients with hematological malignancies and solid tumors. BLOOD, vol. 92, p. 440A-441A, ISSN: 0006-4971

115. Del Poeta G, Venditti A, Aronica G, Buccisano F, Cox MC, Maurillo L, Tamburini A, Bruno A, Masi M, Amadori S (1998). Bcl-2 overexpression identifies a subset of patients with acute myeloid leukemia at worse prognosis within the intermediate/favorable cytogenetic risk group. BLOOD, vol. 92, p. 606A, ISSN: 0006-4971

116. Del Poeta G, Venditti A, Buccisano F, Tamburini A, Cox MC, Aronica G, Maurillo L, Bruno A, Epiceno AM, Del Moro B, Suppo G, Masi M, Amadori S (1998). c-Kit overexpression is linked to high level of bcl-2 and worse clinical outcome in acute myeloid leukemia (AML). BRITISH JOURNAL OF HAEMATOLOGY, vol. 102, p. 102, ISSN: 0007-1048

117. Del Poeta G, Venditti A, Aronica G, Buccisano F, Cox MC, Tamburini A, Maurillo L, Bruno A, Epiceno AM, Del Moro B, Suppo G, Masi M, Amadori S (1998). Overexpression of P-glycoprotein external and internal epitopes predicts prognosis in acute myeloid leukemia. BRITISH JOURNAL OF HAEMATOLOGY, vol. 102, p. 104, ISSN: 0007-1048

118. Buccisano F, Del Poeta G, Venditti A, Tamburini A, Cantonetti M, Cudillo L, Aronica G, Cordero V, Morino L, Maurillo L, Masi M, Amadori S (1998). High-dose

ARAc/mitoxantrone followed by stem cell transplantation for the treatment of poor-risk lymphoid malignancies. BRITISH JOURNAL OF HAEMATOLOGY, vol. 102, p. 229, ISSN: 0007-1048

119. Venditti A, Tamburini A, Buccisano F, Del Poeta G, Aronica G, Bruno A, Maurillo L, Masi M, Amadori S (1998). Low dose cytosine arabinoside and all-trans retinoic acid for the treatment of secondary acute myeloid leukaemia and high risk myelodysplastic syndrome. BRITISH JOURNAL OF HAEMATOLOGY, vol. 102, p. 344, ISSN: 0007-1048

CONTRIBUTI IN VOLUME (Capitolo o Saggio)

1. F Buccisano, D Fraboni, L Maurillo (2013) Capitolo 5: Ruolo dell’immunofenotipo nella diagnostica ematologica e nella determinazione della malattia minima residua. In Ematologia di Mandelli. Piccin

2. A Venditti, L Ottaviani, C Sarlo, L Di Caprio, M Quaresima, S Gumeniuk, M G Cefalo, E Ceresoli, M I Del Principe, Maurillo L, F Buccisano, S Amadori (2009). Leucemia mieloide acuta: Terapie innovative. In: Seminari di Ematologia Oncologica. vol. 3, p. 951-972, Edizioni Internazionali srl Divisione EDIMES Edizioni Medico-Scientifiche – Pavia

3. Maurillo L, Mazzone C, Neri B, Venditti A, Amadori S (2005). Gli anticorpi monoclonali nelle leucemie acute. In: Anticorpi Monoclonali. vol. 2, p. 69-84, Edizioni Internazionali srl Divisione EDIMES Edizioni Medico-Scientifiche – Pavia

4. Amadori S, Maurillo L, Buccisano F, Mazzone C, Venditti A (2003). Leucemie mieloidi acute: aspetti biologici e diagnostici. In: Ematologia Oncologica. p. 1-11, Edizioni Internazionali srl Divisione EDIMES Edizioni Medico-Scientifiche – Pavia

5. Amadori S, Tamburini A, Buccisano F, Maurillo L, Venditti A, Del Poeta G (1998). Chemioterapia mieloablativa con autotrapianto di cellule staminali emopoietiche nelle sindromi mielodisplastiche. In: Progressi in ematologia clinica. vol. 17, p. 43-47, Edizioni Internazionali srl Divisione EDIMES Edizioni Medico-Scientifiche - Pavia

COMPETENZE TECNICO- PROFESSIONALI

1. Partecipazione scientifica a progetti di ricerca internazionali e nazionali,

ammessi al finanziamento sulla base di bandi competitivi che prevedano la revisione tra pari

• PRIN 2002 Valutazione della espressione di molecole di adesione

nelle leucemie acute mieloidi secondarie: implicazioni clinico-biologiche. Durata 14 mesi; ruolo ricoperto: partecipante

• PRIN 2008 Temsirolimus, un inibitore di mTOR, in associazione con

Clofarabina per il trattamento di salvataggio della leucemia acuta mieloide dell'anziano: studio clinico di fase II. Durata 18 mesi; ruolo ricoperto: partecipante

2. Membro del Writing Committee del protocollo GIMEMA AML1310 Risk

adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukaemia - EudraCT number 2010-023809-36

3. Membro delle seguenti Società Scientifiche:

• Società Italiana di Ematologia (SIE) • Società Italiana di Ematologia Sperimentale (SIES) • European Hematology Association (EHA) • American Society of Hematology (ASH)

Roma 09 settembre 2016 Dr Luca Maurillo